Quote:

---

sox040713 Monday, 02/06/17 02:15:05 PM
Re: Amatuer17 post# 171156
Post # of 171213

Leo can't say a trial succeeds when it fails. Leo can't say there aren't safety concerns when there are SAEs.

Quote:What else CEO can say?
He has to be positive.

---

Quote:

---

sox040713 Monday, 02/06/17 03:00:35 PM
Re: Amatuer17 post# 171210
Post # of 171213

The upcoming Phase 2 IV trial will provide valuable PK data for the oral dose optimization trial. I'm just glad that K will finally be dosed three times per week.

Leo Ehrlich

"The upcoming Phase 2a ovarian cancer trial is proceeding with intravenous dosing. We are working toward shifting to all those and study later in 2017 after required bridging toxicology studies are completed."

Arthur P. Bertolino

"We can continue to advance Kevetrin in an IV form without any hesitation. Depending upon the required bridging toxicology studies we may be able to test initial dosing with the oral Kevetrin formulation in healthy volunteers then rapidly transition into those in patients with cancer. Meaning that it would not take long to have the oral and IV Kevetrin at the same point of development."

http://seekingalpha.com/article/4023682-cellc...art=single

---